How to Crack the Problem of Liver Fibrosis After TACE? Absin Antibodies Support the New Scheme of Folic Acid-Targeted Nanoemulsions Published in *Advanced Functional Materials*

I. Clinical Challenge: Post-TACE Hepatic Fibrosis—The "Double-Edged Sword" of Therapeutic Efficacy

Transarterial chemoembolization (TACE) represents the standard of care for intermediate-to-advanced hepatocellular carcinoma (HCC); however, its therapeutic efficacy constitutes a "double-edged sword": while effectively controlling tumor progression, it inevitably exacerbates hepatic fibrosis in patients, significantly compromising long-term prognosis. Although the antifibrotic agent pirfenidone (PFD) demonstrates clinical efficacy, its clinical utility is constrained by poor oral bioavailability and dose-dependent systemic adverse effects resulting from high-dose requirements.

II. Research Strategy: Biomimetic Delivery with Dual-Targeting Capability

To address the aforementioned clinical limitations, the research team engineered a "biomimetic intelligent delivery" strategy based on the following conceptual framework:

1. Construction of a stable nanocarrier: Zein peptide (ZP) and dextran (DEX) were conjugated via the Maillard reaction to form a protein-polysaccharide complex (ZD), serving as a natural nanocarrier for the nanoemulsion. This construct effectively resists gastrointestinal enzymatic degradation, ensuring stable drug delivery.
2. Introduction of active targeting ligand: Folic acid (FA) was further conjugated to generate the ZD-FA carrier. This design exploits the overexpression of folate receptors (FR) on activated hepatic stellate cells (HSCs) and intestinal epithelial cells, achieving dual objectives of enhanced intestinal absorption and targeted hepatic lesion delivery.
3. Efficient drug encapsulation: PFD was encapsulated within the carrier to construct the final oral targeted nanoemulsion formulation, designated PFD@ZD-FA.

III. Research Outcomes: Low-Dose, High-Efficacy with Significant Advantages

The superiority of this nanoemulsion system was validated through comprehensive experimental characterization:

Excellent physicochemical properties: PFD@ZD-FA exhibited uniform particle size (≈45 nm), high drug loading efficiency (>80%), and exceptional stability in simulated gastrointestinal fluids, achieving sustained drug release.

Robust cellular targeting capability: In vitro experiments demonstrated that PFD@ZD-FA is efficiently internalized by activated HSCs via FR-mediated endocytosis, significantly suppressing HSC activation and downregulating fibrogenic biomarkers including α-smooth muscle actin (α-SMA) and collagen types I/III.

Superior in vivo therapeutic efficacy: In hepatic fibrosis rat models and rabbit VX2 hepatocellular carcinoma post-TACE models, low-dose PFD@ZD-FA (100 mg/kg) demonstrated antifibrotic effects superior to high-dose free PFD (150 mg/kg), significantly reducing liver stiffness and improving hepatic function parameters without observable adverse effects.

IV. Critical Role of Absin Products: Providing Reliable Validation for Research Conclusions

The successful completion of this study was supported by high-quality reagents. Two Absin antibodies played indispensable roles in critical data validation:

• 1. Collagen III Antibody (abs120021): In the core mechanistic experiments evaluating antifibrotic efficacy, this antibody (1:1000 dilution) was employed for Western blot and immunohistochemical detection of collagen III expression levels. The experimental results clearly demonstrated that PFD@ZD-FA effectively downregulates collagen III, providing critical evidence for the central conclusion of "antifibrotic activity."
• 2. GAPDH Antibody (abs137959): As a classical loading control antibody, this product (1:5000 dilution) ensured consistency in protein sample loading and accuracy in quantitative results across all Western blot experiments, establishing a solid foundation for the reliability of all target protein data.

V. Summary and Perspectives

This study, published in a premier-tier journal, not only provides a novel, highly efficient, and low-toxicity targeted drug delivery strategy for the treatment of post-TACE hepatic fibrosis, but also reaffirms the substantial potential of folate receptor-based targeted delivery systems in hepatic disease therapeutics. Absin is honored to provide high-quality product support for such cutting-edge research, empowering scientists to continuously overcome challenging research obstacles.

Products Used in This Study

Catalog No.	Product Name	Size
abs120021	Rabbit anti-Collagen III Polyclonal Antibody	50μL/100μL
abs137959	Mouse anti-GAPDH Monoclonal Antibody	50μg

WB-Related Recommendations

Catalog No.	Product Name	Size
abs9116	Lysis Buffer for WB/IP Assays	100 mL
abs9229	RIPA Lysis Buffer (Strong)	100 mL
abs9232	BCA Protein Assay Kit	500 assays
abs954	Dilution Buffer for Primary/Secondary Antibodies (WB)	100 mL
abs920	ECL Chemiluminescence Detection Reagent Kit	25 mL × 2
abs9213	DAB Peroxidase Substrate Kit (Purple-Blue, WB)	1 kit

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. worldwide@absin.cn

Follow us on Facebook: Absin Bio